Your browser doesn't support javascript.
loading
Combined α-programmed death-1 monoclonal antibody blockade and fractionated radiation therapy reduces tumor growth in mouse EL4 lymphoma.
Lin, Xiuyun; Zeng, Tao; Xiong, Jiani; Zhang, Qiong; Jiang, Pan; Li, Xiufeng; Lin, Shuchun; Xu, Qianqian; Weng, Huanjiao; Lai, Haichun; Gong, Huichun; Lin, Jinxiang; Cheng, Niangmei; Tian, Xinling; Xu, Yunlu; Fang, Shubin; Jin, Rong; Chen, Zhiwei; Yang, Jianbo; Morton, Luke; Yueh, Bevan; Lin, Jizhen.
Afiliação
  • Lin X; a Institute of Immunotherapy , Fujian Medical University , Fuzhou , China.
  • Zeng T; b Fujian Medical University Union Hospital , Fuzhou , China.
  • Xiong J; c Immunotherapy Research and Development , CreMab Biopharma, Inc , Fuzhou , China.
  • Zhang Q; a Institute of Immunotherapy , Fujian Medical University , Fuzhou , China.
  • Jiang P; a Institute of Immunotherapy , Fujian Medical University , Fuzhou , China.
  • Li X; a Institute of Immunotherapy , Fujian Medical University , Fuzhou , China.
  • Lin S; c Immunotherapy Research and Development , CreMab Biopharma, Inc , Fuzhou , China.
  • Xu Q; a Institute of Immunotherapy , Fujian Medical University , Fuzhou , China.
  • Weng H; b Fujian Medical University Union Hospital , Fuzhou , China.
  • Lai H; c Immunotherapy Research and Development , CreMab Biopharma, Inc , Fuzhou , China.
  • Gong H; c Immunotherapy Research and Development , CreMab Biopharma, Inc , Fuzhou , China.
  • Lin J; a Institute of Immunotherapy , Fujian Medical University , Fuzhou , China.
  • Cheng N; b Fujian Medical University Union Hospital , Fuzhou , China.
  • Tian X; c Immunotherapy Research and Development , CreMab Biopharma, Inc , Fuzhou , China.
  • Xu Y; c Immunotherapy Research and Development , CreMab Biopharma, Inc , Fuzhou , China.
  • Fang S; a Institute of Immunotherapy , Fujian Medical University , Fuzhou , China.
  • Jin R; c Immunotherapy Research and Development , CreMab Biopharma, Inc , Fuzhou , China.
  • Chen Z; a Institute of Immunotherapy , Fujian Medical University , Fuzhou , China.
  • Yang J; a Institute of Immunotherapy , Fujian Medical University , Fuzhou , China.
  • Morton L; c Immunotherapy Research and Development , CreMab Biopharma, Inc , Fuzhou , China.
  • Yueh B; d Fuzhou Center for Disease Control and Prevention , Fuzhou , China.
  • Lin J; e Department of Otolaryngology , Medical School, University of Minnesota , Minneapolis , Minesota , USA.
Cancer Biol Ther ; 20(5): 666-679, 2019.
Article em En | MEDLINE | ID: mdl-30572778
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Fracionamento da Dose de Radiação / Receptor de Morte Celular Programada 1 / Quimiorradioterapia / Antineoplásicos Imunológicos / Linfoma Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Cancer Biol Ther Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Fracionamento da Dose de Radiação / Receptor de Morte Celular Programada 1 / Quimiorradioterapia / Antineoplásicos Imunológicos / Linfoma Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Cancer Biol Ther Ano de publicação: 2019 Tipo de documento: Article